Email
Text Size A A

HOME ›   FOR RESEARCHERS

OUR FUNDING STRATEGY

Our goal is to accelerate the best ideas in Parkinsonís disease research toward clinical testing and practical relevance for patients. By placing a strong emphasis on translational and clinical research, we ensure that new ideas are constantly flowing into the drug development pipeline.

Our Model

Sitting at the nexus of Parkinsonís research worldwide, we are constantly building and refining our understanding of the therapeutic needs of Parkinsonís patients. Our research agenda is crafted around these needs, reflecting two key areas:

  • Research exploring specific therapeutic approaches that could contribute to the development of improved Parkinson's disease treatments
  • Research to develop tools and resources that will help accelerate the development of Parkinson's disease treatments

Through our annual Pipeline Strategy, we constantly seek new ideas, relevant biological targets and promising therapeutics that can benefit people with Parkinsonís disease. In addition, our team of experts looks for challenge areas where the Foundation's proactive effort can accelerate the development of new and improved treatments. Priority areas allow the Foundation to quickly deploy resources and expertise where it is needed most.

Alpha-Synuclein

A major focus of therapeutic development given its genetic link and presence in Lewy bodies, the cardinal neuropathological feature of Parkinsonís disease.

 

Biomarkers

Biomarkers are critical for identifying and tracking the progression of Parkinsonís disease, as well as detecting how drugs act in the body.

 

Cognition

Not well managed by existing treatments, cognitive impairment is a major Ēnon-motorĒ feature of Parkinsonís disease that can drastically reduce quality of life.

 

Dyskinesia

A major side effect of gold-standard levodopa therapy, dyskinesias can be highly disabling and reduce overall quality of life for Parkinsonís patients.

 

Imaging

Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects.†An imaging biomarker would be extremely useful both for drug development studies and as an outcome measure in clinical trials.†

 

LRRK2

A compelling drug target given its strong genetic link to Parkinsonís disease and highly ďdruggableĒ cellular function.

 

Neurotrophic Factors

Essential for developing and maintaining healthy neurons, neurotrophic factors could help protect and restore function in damaged dopamine neurons in the brains of Parkinsonís patients.

 

Pipeline Strategy

Our Pipeline Strategy, including annual funding programs, is the Foundation's flagship mechanism for funding new and promising research projects.

 

Research Tools

The Foundation offers a variety of critical tools and resources to help investigators spend more time focusing on what matters: curing Parkinsonís disease.

 

 

Accelerate Your Research

Search open funding programs MORE

 

Want Research Updates?

Receive e-news from MJFF about funding opportunities, scientific conferences, and more.

Sign Up Now MORE

 

Access Research Tools

Select from pre-clinical models, reagents, research data and more.

learn more MORE

 

Learn about our impact and funding track record

visit our progress page MORE

visit our grant portfolio MORE

We work with Industry

More than $102†million in funding to over†230†unique industry-led projects

learn more MORE

 

Connect With Other Researchers

Join the conversation on   MORE

 

 

EXISTING MEMBER?

SIGN IN

Close

New to MJFF?  Register Now

 

 

 

  REMEMBER ME

 

Forgot username/password?

 

  Applying for a grant? Sign in here.

EMAIL TO A FRIEND

Close